Related Experiment Video
Updated: Jul 4, 2026
08:10
The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
The 6-hydroxydopamine model: news from the past
Fabio Blandini1, Marie-Therese Armentero, Emilia Martignoni
1Interdepartmental Research Center for Parkinson's Disease (CRIMP), IRCCS Neurological Institute C. Mondino, Via Mondino 2, Pavia, Italy. fabio.blandini@mondino.it
Parkinsonism & Related Disorders
|July 4, 2008
Summary
6-hydroxydopamine (6-OHDA) is a widely used toxin for creating Parkinson's disease models in rats. Its low cost, reproducibility, and versatility make it a valuable tool for studying disease mechanisms.
Area of Science:
- Neuroscience
- Pathophysiology
- Animal Models
Background:
- Investigating Parkinson's disease (PD) mechanisms requires accurate animal models.
- The 6-hydroxydopamine (6-OHDA) model is extensively used for inducing nigrostriatal lesions in rats.
Purpose of the Study:
- To highlight the continued relevance and advantages of the 6-OHDA model in PD research.
- To explain why 6-OHDA remains a preferred neurotoxin despite newer model development.
Main Methods:
- Utilizing 6-hydroxydopamine (6-OHDA) to create experimental Parkinson's disease models.
- Inducing nigrostriatal lesions in rat models via targeted toxin injection.
Main Results:
- The 6-OHDA model offers a reproducible method for creating Parkinson's-like pathology.
- The procedure is cost-effective and adaptable, allowing for varied lesion severity and temporal profiles.
Conclusions:
- The 6-OHDA model's simplicity, reproducibility, and flexibility ensure its ongoing utility in Parkinson's disease research.
- This model remains a cornerstone for studying neurodegenerative processes and testing therapeutic strategies for Parkinson's disease.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...